scholarly journals In Vitro Activity of Disinfectants against Mold Fungi Isolated from Different Environments of the Children’s Medical Center Hospital, Tehran, Iran

2021 ◽  
Author(s):  
Sedighe Karimpour Roshan ◽  
Hatam Godini ◽  
Saham Ansari ◽  
Arezoo Charsizadeh ◽  
Maryam Norouzi
Keyword(s):  
Fungal Pathogens ◽  
Medical Center ◽  
Antifungal Susceptibility ◽  
Vitro Activity ◽  
Hospital Environment ◽  
In Vitro Activity ◽  
Resistant Species ◽  
Susceptibility Tests ◽  
Inert Surfaces

Introduction: Fungal aerosols cause life-threatening infections in patients hospitalized in critical wards. Antiseptics and disinfectants have broad-spectrum antimicrobial activity against the living tissue and inert surfaces microorganisms; hence, they have an essential role in controlling and preventing nosocomial infections. This study aimed to evaluate in vitro antifungal activity of benzalkonium chloride (BAC), chlorhexidine digluconate (CHX), and sodium hypochlorite (SH) against isolated fungal aerosols from the hospital environment. Materials and Methods: The susceptibility tests were performed on fungal aerosols isolated from various wards of Children’s Medical Center, based on broth microdilution antifungal susceptibility testing of filamentous fungi approved by the Clinical and Laboratory Standards Institute (CLSI) M38-A2 document. The isolates included Aspergillus (Aspergillus flavus (n = 14), Aspergillus niger complex (n = 12), Penicillium spp. (n = 14), and Cladosporium spp. (n = 14). Results: The geometric means (GM) of the Minimum Inhibitory Concentrations (MICs) of the biocides across all isolates were as follows: BAC, 3.56 µg/ml, CHX, 9.45 µg/ml, and SH, 810.35 µg/ml. The highest range of MICs was found for SH (50-12800 µg/ml), while the lowest range was for BAC (1-16 µg/ml) against all fungal isolates. Generally, BAC showed the highest in vitro activity among disinfectants tested. The lowest MIC50 and MIC90 values were 4 and 8 µg/ml for BAC, followed by 16 and 32 µg/ml for CHX, and 800 and 6400 µg/ml for SH, respectively. Conclusion: The findings showed that BAC was an effective disinfectant, which can  prevent resistant species and fungal pathogens and be used an alternative to other disinfectants and antiseptics.

In vitro activity of olorofim against clinical isolates of Scedosporium species and Lomentospora prolificans using EUCAST and CLSI methodologies

2020 ◽  
Vol 75 (12) ◽  
pp. 3582-3585
Author(s):  
Olga Rivero-Menendez ◽  
Manuel Cuenca-Estrella ◽  
Ana Alastruey-Izquierdo
Keyword(s):  
Amphotericin B ◽  
Susceptibility Testing ◽  
Antifungal Susceptibility ◽  
Vitro Activity ◽  
Clinical Isolates ◽  
Scedosporium Apiospermum ◽  
In Vitro Activity ◽  
Scedosporium Dehoogii ◽  
Scedosporium Species

Abstract Objectives To evaluate the in vitro activity of olorofim, a new broad-spectrum antifungal with a novel mechanism of action, against a collection of 123 Spanish clinical isolates belonging to five Scedosporium species and Lomentospora prolificans. Methods The activity of olorofim against Scedosporium apiospermum (n = 30), Scedosporium boydii (n = 30), Scedosporium ellipsoideum (n = 10), Scedosporium aurantiacum (n = 20), Scedosporium dehoogii (n = 3) and Lomentospora prolificans (n = 30) was compared with that of amphotericin B, voriconazole, isavuconazole and micafungin by performing EUCAST and CLSI reference methods for antifungal susceptibility testing. Results Amphotericin B and isavuconazole showed MICs ≥2 mg/L for all the species evaluated and voriconazole was moderately active (GM, MIC50 and MIC90 values ≤2 mg/L) against all of them except L. prolificans. Micafungin was effective against S. apiospermum complex strains, but exhibited elevated MECs for S. dehoogii and S. aurantiacum. Olorofim showed low MICs for all the Scedosporium strains tested (GM values were lower than 0.130 and 0.339 by the EUCAST method and the CLSI method, respectively, for all of the species), including those belonging to the MDR species L. prolificans, for which GM values were 0.115 and 0.225 mg/L by the EUCAST method and the CLSI method, respectively, while the GMs for the rest of the antifungals evaluated were higher than 3.732 mg/L using both methodologies. Conclusions Olorofim displayed promising in vitro activity against the Scedosporium and L. prolificans strains tested, some of which have reduced susceptibility to the antifungals that are currently in use.

In vitro activity of the aryl-fluoroquinolones A-56619 and A-56620 and evaluation of disk susceptibility tests

1986 ◽  
Vol 5 (1) ◽  
pp. 18-22 ◽  
Author(s):  
A. L. Barry ◽  
R. N. Jones ◽  
C. Thornsberry ◽  
L. W. Ayers ◽  
T. L. Gavan ◽  
...  
Keyword(s):  
Vitro Activity ◽  
In Vitro Activity ◽  
Susceptibility Tests ◽  
Disk Susceptibility

In Vitro Activity of Posaconazole and Comparators versus Opportunistic Filamentous Fungal Pathogens Globally Collected During 8 Years

2021 ◽  
pp. 115473
Author(s):  
Michael A. Pfaller ◽  
Cecilia G. Carvalhaes ◽  
Shawn A. Messer ◽  
Paul R. Rhomberg ◽  
Mariana Castanheira
Keyword(s):  
Fungal Pathogens ◽  
Vitro Activity ◽  
In Vitro Activity

scholarly journals In Vitro Activity of Ibrexafungerp against a Collection of Clinical Isolates of Aspergillus, Including Cryptic Species and Cyp51A Mutants, Using EUCAST and CLSI Methodologies

2021 ◽  
Vol 7 (3) ◽  
pp. 232
Author(s):  
Olga Rivero-Menendez ◽  
Juan Carlos Soto-Debran ◽  
Manuel Cuenca-Estrella ◽  
Ana Alastruey-Izquierdo
Keyword(s):  
Cryptic Species ◽  
Antifungal Susceptibility ◽  
Sensu Stricto ◽  
Vitro Activity ◽  
Clinical Isolates ◽  
Moderate Activity ◽  
In Vitro Activity ◽  
Synthesis Inhibitor ◽  
Complex Species

Ibrexafungerp is a new orally-available 1,3-β-D-glucan synthesis inhibitor in clinical development. Its in vitro activity and that of amphotericin B, voriconazole, and micafungin were evaluated against a collection of 168 clinical isolates of Aspergillus spp., including azole–susceptible and azole–resistant (Cyp51A mutants) Aspergillus fumigatus sensu stricto (s.s.) and cryptic species of Aspergillus belonging to six species complexes showing different patterns of antifungal resistance, using EUCAST and CLSI antifungal susceptibility testing reference methods. Ibrexafungerp displayed low geometric means of minimal effective concentrations (MECs) against A. fumigatus s.s. strains, both azole susceptible (0.040 mg/L by EUCAST and CLSI versus 1.231 mg/L and 0.660 mg/L for voriconazole, respectively) and azole resistant (0.092 mg/L and 0.056 mg/L, EUCAST and CLSI, while those for voriconazole were 2.144 mg/L and 2.000 mg/L). Ibrexafungerp was active against most of the cryptic species of Aspergillus tested, yielding MEC values only comparable to those of micafungin. Nevertheless, this new compound exhibited a moderate activity against A. ustus complex species, MECs ≥ 0.5 mg/L against Aspergillus insuetus and Aspergillus keveii strains, and was inactive against the Aspergillus alliaceus isolates tested (MEC90s ≥ 16 mg/L). All in all, ibrexafungerp shows encouraging in vitro results against cryptic species of Aspergillus and azole–susceptible and azole resistant strains of A. fumigatus, some of which are difficult to treat using the available therapeutic options.

scholarly journals In Vitro Activity of Moxifloxacin against 923 Anaerobes Isolated from Human Intra-Abdominal Infections

2006 ◽  
Vol 50 (1) ◽  
pp. 148-155 ◽  
Author(s):  
Ellie J. C. Goldstein ◽  
Diane M. Citron ◽  
Yumi A. Warren ◽  
Kerin L. Tyrrell ◽  
C. Vreni Merriam ◽  
...  
Keyword(s):  
Bacteroides Fragilis ◽  
Vitro Activity ◽  
Dilution Method ◽  
Agar Dilution Method ◽  
Species Variation ◽  
In Vitro Activity ◽  
Resistant Species ◽  
Agar Dilution ◽  
Abdominal Infections

ABSTRACT The in vitro activity of moxifloxacin against 923 recent anaerobic isolates obtained from pretreatment cultures in patients with complicated intra-abdominal infections was studied using the CLSI M11-A-6 agar dilution method. Moxifloxacin was active against 87% (96 of 110) Bacteroides fragilis strains at ≤1 μg/ml and 87% (79 of 90) B. thetaiotaomicron strains at ≤2 μg/ml. Species variation was seen, with B. uniformis, B. vulgatus, Clostridium clostridioforme, and C. symbiosum being least susceptible and accounting for most of the resistant isolates; excluding the aforementioned four resistant species, 86% (303 of 363) of Bacteroides species isolates and 94% (417 of 450) of all other genera and species were susceptible to ≤2 μg/ml of moxifloxacin. Overall, moxifloxacin was active against 763 of 923 (83%) of strains at ≤2 μg/ml, supporting its use as a monotherapy for some community-acquired intra-abdominal infections.

scholarly journals In Vitro Activity of Carbosilane Cationic Dendritic Molecules on Prevention and Treatment of Candida Albicans Biofilms

Pharmaceutics ◽  
2020 ◽  
Vol 12 (10) ◽  
pp. 918
Author(s):  
Irene Heredero-Bermejo ◽  
Natalia Gómez-Casanova ◽  
Sara Quintana ◽  
Juan Soliveri ◽  
Francisco Javier de la Mata ◽  
...  
Keyword(s):  
Cell Viability ◽  
Biofilm Formation ◽  
Fungal Pathogens ◽  
Resistance Mechanisms ◽  
Antifungal Drugs ◽  
Vitro Activity ◽  
In Vitro Activity ◽  
Candida Spp ◽  
Screening Process

Candida spp. are one of the most common fungal pathogens. Biofilms formed by Candidaalbicans offer resistance mechanisms against most antifungal agents. Therefore, development of new molecules effective against these microorganisms, alone or in combination with antifungal drugs, is extremely necessary. In the present work, we carried out a screening process of different cationic carbosilane dendritic molecules against C. albicans. In vitro activity against biofilm formation and biofilms was tested in both Colección Española de Cultivos Tipo (CECT) 1002 and clinical C. albicans strains. Cytotoxicity was studied in human cell lines, and biofilm alterations were observed by scanning electron microscopy (SEM). Antifungal activity of the carbosilane dendritic molecules was assessed by monitoring cell viability using both established and novel cell viability assays. One out of 14 dendritic molecules tested, named BDSQ024, showed the highest activity with a minimum biofilm inhibitory concentration (MBIC) for biofilm formation and a minimum biofilm damaging concentration (MBDC) for existing biofilm of 16–32 and 16 mg/L, respectively. Synergy with amphotericin (AmB) and caspofungin (CSF) at non-cytotoxic concentrations was found. Therefore, dendritic compounds are exciting new antifungals effective at preventing Candida biofilm formation and represent a potential novel therapeutic agent for treatment of C. albicans infection in combination with existing clinical antifungals.

Sign in / Sign up

Export Citation Format

Share Document